JGC
TGTX icon

J. Goldman & Co’s TG Therapeutics TGTX Stock Holding History

J. Goldman & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,235
Closed -$1.6M – 922
2026
Q1 		$1.6M Buy
48,235
+4,044
+9% +$121K 0.05% 358
2025
Q4 		$1.32M Sell
44,191
-825
-2% -$26.9K 0.03% 358
2025
Q3 		$1.63M Buy
45,016
+13,766
+44% +$453K 0.04% 294
2025
Q2 		$1.12M Buy
31,250
+23,214
+289% +$864K 0.03% 331
2025
Q1 		$317K Hold
8,036
– – 0.01% 420
2024
Q4 		$242K Sell
8,036
-34,751
-81% -$997K 0.01% 398
2024
Q3 		$1M Buy
+42,787
New +$934K 0.03% 297
2023
Q3 		– Sell
-179,346
Closed -$4.45M – 479
2023
Q2 		$4.45M Buy
+179,346
New +$4.63M 0.16% 149
2021
Q2 		– Sell
-41,305
Closed -$1.99M – 518
2021
Q1 		$1.99M Buy
41,305
+9,591
+30% +$461K 0.06% 243
2020
Q4 		$1.65M Buy
+31,714
New +$1.07M 0.08% 206
2020
Q3 		– Sell
-132,414
Closed -$2.58M – 382
2020
Q2 		$2.58M Buy
132,414
+104,631
+377% +$1.69M 0.16% 142
2020
Q1 		$273K Buy
+27,783
New +$351K 0.03% 203

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

J. Goldman & Co's TGTX Position: Q2 2026 in Review

J. Goldman & Co sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 48,235 shares — an estimated $1.6M sold.

J. Goldman & Co first reported a position in TGTX in Q1 2020 and held it in 12 quarters. The position peaked at $4.45M in Q2 2023. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • J. Goldman & Co reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 48,235 TG Therapeutics shares in Q2 2026, an estimated $1.6M.
  • J. Goldman & Co first reported a position in TG Therapeutics in Q1 2020 and held it in 12 quarters.
  • J. Goldman & Co's TG Therapeutics position peaked at $4.45M in Q2 2023.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.